Last reviewed · How we verify
NCT04840069
Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma
Phase 2 trial testing Fluciclovine PET guided Radiotherapy in Newly Diagnosed Glioblastoma in 100 participants. Status unknown.
30 March 2024
Quick facts
| Lead sponsor | St. Joseph's Hospital and Medical Center, Phoenix |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 7 June 2021 |
| Primary completion | 30 March 2024 |
| Estimated completion | 30 March 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fluciclovine PET guided Radiotherapy — full drug profile →
Conditions studied
- Newly Diagnosed Glioblastoma — all drugs for Newly Diagnosed Glioblastoma →
Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Who can join
18 and older, any sex, with Newly Diagnosed Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the this study is to see if the use of a PET scan with 18F-fluciclovine (PET or Fluciclovine PET) in addition to the normal radiation planning imaging procedures (MRI and CT scan) will help determine the areas where the radiation therapy is to be delivered. It is also a goal of the study to determine if subjects live longer when treatment plans for radiation therapy are designed using a Fluciclovine PET scan, as well as MRI and CT scans. We will also collect information on if and where the tumor returns. Information on the side effects from the two different treatment planning imaging methods will also be collected. 18F-Fluciclovine is an FDA-approved radioactive diagnostic agent that is injected into the patient and then taken up by cancer cells, which can then be visualized with a PET/CT scan. 18F-Fluciclovine is FDA approved for the detection of recurrent prostate cancer, but is still investigational for the purposes of this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04840069
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Newly Diagnosed Glioblastoma
Currently open trials in the same condition.
- NCT06816927 — Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab · Phase 2 · recruiting
- NCT06622434 — New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study · Phase 1, PHASE2 · recruiting
- NCT05235737 — The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab · Phase 4 · recruiting
- NCT04600817 — A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Comple · Phase 2 · active not recruiting
- NCT04477200 — Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma · Phase 1 · active not recruiting
Other St. Joseph's Hospital and Medical Center, Phoenix trials
Trials by the same sponsor.
- NCT06177028 — MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment · Phase 2 · not yet recruiting
- NCT06734286 — Working Memory Training in Patients with Mild Cognitive Impairment · NA · recruiting
- NCT06578195 — ASSESS ALL ALS Study · recruiting
- NCT06581861 — PREVENT ALL ALS Study · recruiting
- NCT06019793 — Electrophysiological Recordings from Deep Brain Stimulation Electrodes for Pain · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04840069 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St. Joseph's Hospital and Medical Center, Phoenix
- Last refreshed: 13 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04840069.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing